Bicycle Therapeutics Stock Performance
| BCYC Stock | USD 9.69 0.06 0.62% |
The firm shows a Beta (market volatility) of 0.8, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicycle Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicycle Therapeutics is expected to be smaller as well. At this point, Bicycle Therapeutics has a negative expected return of -0.68%. Please make sure to confirm Bicycle Therapeutics' treynor ratio, and the relationship between the standard deviation and kurtosis , to decide if Bicycle Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bicycle Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.62 | Five Day Return (8.50) | Year To Date Return (32.52) | Ten Year Return (19.25) | All Time Return (19.25) |
1 | Acquisition by Baker Bros. Advisors Lp of 42369 shares of Bicycle Therapeutics at 15.3418 subject to Rule 16b-3 | 12/16/2024 |
2 | Insider Trading | 12/27/2024 |
3 | Acquisition by Baker Bros. Advisors Lp of 8801 shares of Bicycle Therapeutics at 14.0 subject to Rule 16b-3 | 01/02/2025 |
4 | Disposition of 2686 shares by Travis Thompson of Bicycle Therapeutics at 15.0 subject to Rule 16b-3 | 01/06/2025 |
5 | Disposition of 9038 shares by Lee Kevin of Bicycle Therapeutics at 14.09 subject to Rule 16b-3 | 01/10/2025 |
6 | Bicycle Therapeutics Given Buy Rating at HC Wainwright | 01/13/2025 |
7 | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/03/2025 |
8 | WESTFIELD CAPITAL MANAGEMENT CO LP Increases Stake in Bicycle Therapeutics PLC | 02/11/2025 |
9 | Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results | 02/25/2025 |
10 | Acquisition by Travis Thompson of 43500 shares of Bicycle Therapeutics at 14.0 subject to Rule 16b-3 | 03/06/2025 |
11 | Bicycle Therapeutics Buy Rating Reaffirmed at Needham Company LLC - Defense World | 03/12/2025 |
| Begin Period Cash Flow | 527 M |
Bicycle |
Bicycle Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,512 in Bicycle Therapeutics on December 14, 2024 and sell it today you would lose (543.00) from holding Bicycle Therapeutics or give up 35.91% of portfolio value over 90 days. Bicycle Therapeutics is currently does not generate positive expected returns and assumes 3.4045% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Bicycle, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bicycle Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicycle Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bicycle Therapeutics, and traders can use it to determine the average amount a Bicycle Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2005
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCYC |
Estimated Market Risk
| 3.4 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.68 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bicycle Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bicycle Therapeutics by adding Bicycle Therapeutics to a well-diversified portfolio.
Bicycle Therapeutics Fundamentals Growth
Bicycle Stock prices reflect investors' perceptions of the future prospects and financial health of Bicycle Therapeutics, and Bicycle Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bicycle Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (18.25) % | ||||
| Current Valuation | (150.32 M) | ||||
| Shares Outstanding | 47.71 M | ||||
| Price To Earning | (3.31) X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 18.89 X | ||||
| Revenue | 35.27 M | ||||
| Gross Profit | (137.69 M) | ||||
| EBITDA | (164.89 M) | ||||
| Net Income | (169.03 M) | ||||
| Cash And Equivalents | 372.77 M | ||||
| Cash Per Share | 12.56 X | ||||
| Total Debt | 3.99 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.88 X | ||||
| Book Value Per Share | 11.48 X | ||||
| Cash Flow From Operations | (164.72 M) | ||||
| Earnings Per Share | (2.90) X | ||||
| Market Capitalization | 666.42 M | ||||
| Total Asset | 956.87 M | ||||
| Retained Earnings | (680.79 M) | ||||
| Working Capital | 861.38 M | ||||
| Current Asset | 103.53 M | ||||
| Current Liabilities | 8.46 M | ||||
About Bicycle Therapeutics Performance
By analyzing Bicycle Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Bicycle Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bicycle Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bicycle Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about Bicycle Therapeutics performance evaluation
Checking the ongoing alerts about Bicycle Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bicycle Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bicycle Therapeutics generated a negative expected return over the last 90 days | |
| Bicycle Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 35.27 M. Net Loss for the year was (169.03 M) with loss before overhead, payroll, taxes, and interest of (137.69 M). | |
| Bicycle Therapeutics currently holds about 372.77 M in cash with (164.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bicycle Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Bicycle Therapeutics Buy Rating Reaffirmed at Needham Company LLC - Defense World |
- Analyzing Bicycle Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bicycle Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bicycle Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bicycle Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bicycle Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bicycle Therapeutics' stock. These opinions can provide insight into Bicycle Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bicycle Stock analysis
When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |